JINLING PHARM.: Olaratumab tablets approved to conduct Phase III clinical research
JINLING PHARM. announced that its subsidiary JINLING Pharmaceutical Factory has received approval from the National Medical Products Administration to conduct Phase III clinical research on Elagolix tablets. Elagolix tablets are a GnRH antagonist primarily used to treat moderate to severe pain associated with endometriosis. This drug has been included in the national "Second Batch of Encouraged Generic Drug List."
According to the Zhitong Finance APP, JINLING PHARM. (000919.SZ) announced that its subsidiary, Nanjing JINLING Pharmaceutical Factory (referred to as "JINLING Pharmaceutical Factory"), has received the clinical trial application acceptance notice for Elagolix from the National Medical Products Administration. Recently, JINLING Pharmaceutical Factory received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, approving the initiation of Phase III clinical research for Elagolix.
Elagolix is an oral gonadotropin-releasing hormone (GnRH) antagonist primarily used to treat moderate to severe pain associated with endometriosis. Elagolix is currently included in the national "Second Batch of Encouraged Generic Drug Catalog."
